Calculate by QxMD
Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 200 decision support tools available • get the app for iOS, Android or Windows at qx.md/calculate
In general, treatment with erythropoietin (EPO) may improve anemia in about 15-20% of patients with myelodysplastic syndromes (MDS). The combination of EPO and granulocyte colony-stimulating factor (GCSF) may improve response rates to ~40%. This predictive model uses two variables (serum EPO and transfusion need) to identify those who are most likely to respond to these stem-cell factors. The model was developed and validated predominantly in patients with low-risk MDS. Response is defined as a 100% reduction in RBC transfusion need or an increase in hemoglobin level by at least 1.5 g/L.
This formula is taken from Hellstrom-Lindberg et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haem 1997;99:344-351.